INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Sarepta Therapeutics, Inc.
August 30 2019 - 8:10PM
Business Wire
--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is
investigating potential claims against Sarepta Therapeutics, Inc.
(“Sarepta” or the “Company”) (NASDAQ: SRPT). This investigation
concerns whether Sarepta has violated federal securities laws
and/or engaged in other unlawful business practices.
On August 19, 2019, Sarepta announced receipt of a Complete
Response Letter (“CRL”) from the U.S. Food & Drug
Administration regarding the Company’s New Drug Application seeking
accelerated approval of golodirsen injection for the treatment of
Duchenne muscular dystrophy. Sarepta disclosed that “[t]he CRL
generally cites two concerns: the risk of infections related to
intravenous infusion ports and renal toxicity seen in pre-clinical
models of golodirsen and observed following administration of other
antisense oligonucleotides.” On this news, the Company’s share
price fell $18.24 per share, or 15.2%, to close at $102.07 on
August 20, 2019.
If you acquired Sarepta securities, have information, or would
like to learn more about these claims, please contact Thomas W.
Elrod of Kirby McInerney LLP at 212-371-6600, by email at
investigations@kmllp.com, or by filling out this contact form, to
discuss your rights or interests with respect to these matters
without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm
concentrating in securities, antitrust, and whistleblower
litigation. The firm’s efforts on behalf of shareholders in
securities litigation have resulted in recoveries totaling billions
of dollars. Additional information about the firm can be found at
Kirby McInerney LLP’s website: www.kmllp.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190830005420/en/
Kirby McInerney LLP Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com www.kmllp.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024